About Neurotrope (NASDAQ:NTRP)
Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardioprotection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a technology license and services agreement with Cognitive Research Enterprises, Inc. and its affiliate NRV II, LLC. The company was founded in 2012 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTRP
CUSIPN/A
Phone973-242-0005
Debt
Debt-to-Equity RatioN/A
Current Ratio10.59%
Quick Ratio10.59%
Price-To-Earnings
Trailing P/E Ratio-1.46
Forward P/E Ratio-6.04
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.88 per share
Price / Book4.56
Profitability
EPS (Most Recent Fiscal Year)($5.69)
Net Income$-12,610,000.00
Net MarginsN/A
Return on Equity-85.03%
Return on Assets-77.32%
Miscellaneous
Employees5
Outstanding Shares7,900,000
Neurotrope (NASDAQ:NTRP) Frequently Asked Questions
What is Neurotrope's stock symbol?
Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."
How were Neurotrope's earnings last quarter?
Neurotrope (NASDAQ:NTRP) released its quarterly earnings data on Friday, August, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.03. View Neurotrope's Earnings History.
What price target have analysts set for NTRP?
2 brokerages have issued 1 year target prices for Neurotrope's shares. Their forecasts range from $15.00 to $31.00. On average, they expect Neurotrope's share price to reach $23.00 in the next twelve months. View Analyst Ratings for Neurotrope.
Who are some of Neurotrope's key competitors?
Some companies that are related to Neurotrope include Affimed (AFMD), BioDelivery Sciences International (BDSI), Galectin Therapeutics (GALT), Checkpoint Therapeutics (CKPT), Axovant Sciences (AXON), Adamis Pharmaceuticals (ADMP), OncoMed Pharmaceuticals (OMED), Otonomy (OTIC), AcelRx Pharmaceuticals (ACRX), ContraFect (CFRX), Merrimack Pharmaceuticals (MACK), Bellerophon Therapeutics (BLPH), Infinity Pharmaceuticals (INFI), ProQR Therapeutics (PRQR), Conatus Pharmaceuticals (CNAT), Trevena (TRVN), CytoDyn (CYDY) and Leap Therapeutics (LPTX).
Who are Neurotrope's key executives?
Neurotrope's management team includes the folowing people:
- Dr. Daniel L. Alkon M.D., Co-Founder, Pres & Chief Scientific Officer (Age 76)
- Mr. Robert Weinstein, CFO, Treasurer, Sec. Corp., Exec. VP & Compliance Officer (Age 58)
- Mr. Charles S. Ramat, Consultant (Age 67)
- Dr. Charles S. Ryan, CEO & Director (Age 54)
- Mr. Jeffrey Benison, Director of Corp. Communications
Has Neurotrope been receiving favorable news coverage?
Media coverage about NTRP stock has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neurotrope earned a coverage optimism score of 0.09 on Accern's scale. They also assigned news stories about the company an impact score of 44.49 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of Neurotrope?
Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neurotrope's stock price today?
One share of NTRP stock can currently be purchased for approximately $8.58.
How big of a company is Neurotrope?
Neurotrope has a market capitalization of $68.30 million. The company earns $-12,610,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Neurotrope employs 5 workers across the globe.
How can I contact Neurotrope?
Neurotrope's mailing address is 205 EAST 42ND STREET 17TH FLOOR, NEW YORK NY, 10017. The company can be reached via phone at 973-242-0005 or via email at [email protected]
MarketBeat Community Rating for Neurotrope (NTRP)
MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe NTRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Neurotrope (NASDAQ:NTRP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Neurotrope in the last 12 months. Their average twelve-month price target is $23.00, suggesting that the stock has a possible upside of 168.07%. The high price target for NTRP is $31.00 and the low price target for NTRP is $15.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $23.00 | $23.00 | $31.00 | $31.00 |
| Price Target Upside: | 168.07% upside | 163.46% upside | 344.76% upside | 344.76% upside |
Neurotrope (NASDAQ:NTRP) Consensus Price Target History
Neurotrope (NASDAQ:NTRP) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/8/2018 | Roth Capital | Initiated Coverage | Buy -> Buy | $15.00 | Medium |  |
| 5/2/2017 | Aegis | Reiterated Rating | Buy | $31.00 | N/A | |
(Data available from 4/19/2016 forward)
Neurotrope (NASDAQ:NTRP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Neurotrope (NASDAQ NTRP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.45%
Institutional Ownership Percentage: 13.93%
Neurotrope (NASDAQ NTRP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/15/2018 | James Gottlieb | Director | Sell | 314 | $8.42 | $2,643.88 | | |
| 12/2/2016 | Bruce Bernstein | Director | Buy | 50,000 | $0.28 | $14,000.00 | 50,000 | |
| 11/23/2016 | Kenneth J Gorelick | Director | Buy | 5,000 | $0.29 | $1,450.00 | 10,000 | |
| 8/26/2016 | Kenneth J Gorelick | Director | Buy | 5,000 | $0.41 | $2,050.00 | 5,000 | |
| 11/23/2015 | James Gottlieb | Director | Buy | 10,000 | $0.59 | $5,900.00 | 5,000 | |
(Data available from 1/1/2013 forward)
Neurotrope (NASDAQ NTRP) News Headlines
| Source: |
|
Neurotrope (NASDAQ:NTRP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Neurotrope (NASDAQ NTRP) Stock Chart for Thursday, April, 19, 2018
Loading chart…
